“Science, b*tch” - Jesse Pinkman Eli Lilly, probably
Dave Ricks is back on his biotech BS. Eli Lilly is officially in advanced talks to gooble gobble up Kelonia Therapeutics for north of $2 billion, per the Wall Street Journal, with a deal potentially landing as soon as this week… because you know, the $2.4 billion Orna deal in February didn't quite scratch the itch. (That's 3 acquisitions in 3 months. Somebody call a sponsor.)
For the uninitiated, Kelonia is a Boston-based clinical-stage biotech building in vivo CAR-T cell therapies. Translation: they can reprogram your immune cells to hunt cancer without yeeting them out of your body first. Traditional CAR-T requires extracting a patient's T-cells, engineering them in a lab for weeks, then reinfusing them at a bigly $400K+. Kelonia's approach skips the whole fat production line that results in one infusion, no chemo prep, done.
And the early data is as juicy as Kelly Clarkson pre-Ozempic . At ASH 2025, Kelonia's lead candidate KLN-1010 posted a 100% MRD-negative response rate in Phase 1. Zero severe cytokine release syndrome. Zero neurotoxicity. For a therapy that usually comes with side effects scarier than the diagnosis, that's a hell of a debut. (Four patients. Lilly's paying roughly $500M per clean response. Proceed accordingly.)
Which means this just continues Lilly's 2026 acquisition CVS-receipt like binge. So far, they’ve snatched up Ventyx Biosciences for $1.2 billion in January. Orna Therapeutics for $2.4 billion in February. An $8.85 billion collab with Innovent Biologics. Now Kelonia for $2B+. Compulsive biotech hoarding Strategic portfolio diversification. Fun fact: Orna was also an in vivo CAR-T play. Ricks didn't just dip his proverbial pen in that ink, he went back and bought the whole inkwell.
Dave "Add to Cart" Ricks told Fortune in March that AI is "not particularly good" at solving biology. Naturally, his solution was to skip the algorithm and just buy the biologists. The $880 billion company has dropped roughly $6 billion on biotech acquisitions in 2026 alone. In other words, the Kelonia price tag clocks in at about two weeks of Mounjaro revenue.
So what's the real play then? Mounjaro and Zepbound printed $39.5 billion in the first nine months of 2025. The oral pill Foundayo just got the FDA nod. And now, the weight loss empire is printing cash, and Ricks is funneling it straight into oncology.
As for Verzenio, its flattening at $5.7 billion. Jaypirca still needs to prove it belongs. The cancer portfolio needs firepower, and in vivo CAR-T might be the biggest money shot in a generation. If this tech works at scale, you're looking at a world where a $400K bespoke nightmare becomes an off-the-shelf infusion. Kelonia already had a J&J collab moving in that direction. Lilly saw the receipts, and I'd bet my Zepound prescription they're not done shopping.
Place your bets accordingly, friends. Until next time…

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.
Did you find this insightful?
Bad
Just Okay
Amazing
Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer
